Related Experiment Video
Updated: Jun 4, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
G9a/GLP Modulators: Inhibitors to Degraders
Anirban Mukherjee1, Takayoshi Suzuki1
1SANKEN, Osaka University, Mihogaoka, Ibaraki-shi, Osaka 567-0047, Japan.
G9a, a key epigenetic enzyme, regulates DNA and gene expression. Inhibiting G9a shows promise for treating cancers and Alzheimer's disease by targeting aberrant methylation patterns.
Area of Science:
- Epigenetics
- Molecular Biology
- Biochemistry
Background:
- Histone methylation is a critical epigenetic mechanism.
- G9a (a histone methyltransferase) methylates H3K9 and H3K27.
- G9a also influences DNA methylation, replication, and repair.
Purpose of the Study:
- To review the role of G9a in cellular processes and disease.
- To highlight G9a as a therapeutic target.
- To discuss the advancement of G9a modulators.
Main Methods:
- Literature review of G9a function and inhibition.
- Analysis of G9a's role in cancer and Alzheimer's disease.
- Evaluation of G9a inhibitors and degraders.
Main Results:
- G9a dysregulation is linked to cancer initiation, progression, and metastasis.
- Aberrant H3K9 dimethylation is observed in Alzheimer's disease.
- Numerous G9a inhibitors/degraders have been identified.
Conclusions:
- G9a is a significant epigenetic regulator with implications in various diseases.
- G9a modulators represent promising therapeutic candidates.
- Targeting G9a offers potential for treating cancer and neurodegenerative disorders.
More Related Videos
00:12A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
Published on: September 22, 2019
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Related Concept Videos
Activation and Inactivation of G Proteins
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...